sever
week
franc
face
un
unpreced
epidem
forc
care
system
make
rapid
farreach
adjust
channel
resourc
toward
care
person
infect
balanc
ensur
continu
provis
necessari
patient
health
emerg
set
impact
treatment
periton
cancer
diseas
clearli
defin
case
goldstandard
cur
treatment
combin
complet
cytoreduct
surgeri
sometim
major
extens
hypertherm
intraperiton
chemotherapi
hipec
scant
still
insuffici
epidemiolog
data
report
excess
mortal
risk
patient
infect
palli
care
pressur
intraperiton
aerosol
chemotherapi
pipac
alon
combin
system
chemotherapi
therapeut
approach
propos
expert
center
also
requir
time
oper
room
pipac
still
evalu
yet
prove
efficaci
phase
iii
cancer
condit
local
nation
govern
bodi
mostli
opt
deschedul
major
surgeri
priorit
system
chemotherapi
delay
strategi
without
yet
plan
later
care
impact
chang
therapeut
strategi
prognosi
patient
elig
cur
care
patient
potenti
elig
neoadjuv
treatment
receiv
palli
treatment
mark
deserv
analysi
aim
cairncarcinomatosi
prospect
observ
studi
conduct
bigrenap
group
first
patient
inclus
made
second
french
cohort
promot
frenchspeak
cancer
feder
ffcd
collect
data
patient
cancer
gain
knowledg
diseas
associ
data
collect
exist
evid
must
consid
periton
cancer
pseudomyxoma
peritonei
respond
system
chemotherapi
weakli
cancer
prolong
preoper
chemotherapi
neg
impact
prognosi
eg
periton
mesothelioma
still
controversi
eg
resect
ovarian
carcinoma
still
cancer
site
respons
system
chemotherapi
uncertain
eg
gastric
colorect
make
progress
difficult
task
cope
demand
epidem
term
mobil
resourc
ensur
continu
care
owe
patient
bigrenap
group
page
j
u
r
n
l
p
r
e
p
r
f
offer
propos
way
forward
rather
guidelin
help
practition
local
nation
govern
entiti
make
inform
choic
last
decad
major
advanc
help
optim
select
patient
set
periop
care
therebi
markedli
reduc
morbid
effici
network
organ
twice
certifi
french
nation
cancer
institut
inca
renap
allow
practic
gener
nationwid
one
fundament
featur
improv
patient
select
gener
exploratori
laparoscopi
examin
offer
higher
sensit
evalu
small
intestin
involv
necessari
determin
patient
resect
set
epidem
suspend
intervent
prefer
periton
mri
option
consid
patient
involv
infect
must
antineoplasia
treatment
suspend
close
monitor
necessarili
hospit
treatment
reassess
everi
two
week
base
propos
present
accord
evolut
infect
cancer
advent
unpreced
situat
produc
highli
uneven
pattern
adapt
among
differ
health
center
across
franc
purpos
critic
rather
rais
awar
need
ensur
care
provis
patient
periton
cancer
ensur
continu
equiti
care
process
narrow
therapeut
indic
engag
right
healthcar
author
respond
set
place
organ
clearli
separ
care
facil
french
nation
digest
cancer
thesauru
tncd
describ
five
phase
epidem
influenc
strateg
choic
accord
impact
healthcar
capac
phase
deschedul
mani
surgic
oper
periton
cancer
seem
excess
except
patient
risk
sever
form
infect
buildup
patient
await
care
caus
increas
timetosurgeri
perand
postepidem
result
loss
life
chanc
patient
phase
shortag
materi
human
resourc
caus
mani
deferr
major
surgeri
phase
probabl
obvious
justifi
suspend
major
surgeri
howev
forwardplan
solut
extern
care
ringfenc
center
probabl
implement
phase
constitut
specif
circuit
clariti
avail
project
mean
enabl
delay
deschedul
cancer
care
priorit
nonurg
care
priorit
must
impos
author
govern
bodi
minim
loss
life
chanc
caus
modif
care
strategi
phase
stage
given
like
shortag
human
resourc
gradual
free
bed
intens
care
mean
must
alloc
prioriti
absorb
backlog
delay
deschedul
surgeri
whichev
epidem
phase
restrict
usual
select
criteria
necessari
purpos
new
preoper
assess
report
screen
infect
thoracoabdominopelv
ct
scan
periton
mri
read
design
expert
radiologist
help
stricter
select
assess
new
benefitriskmean
balanc
deschedul
surgic
explor
probabl
nonresect
deem
high
deferr
risk
postop
complic
link
number
digest
resect
seem
great
screen
pneumonia
phase
give
prioriti
resourc
cur
cancer
surgeri
intern
recommend
psogi
euracan
drawn
use
procedur
pseudomyxoma
specifi
three
pictur
immedi
resect
oper
patient
ii
nonresect
andor
nonoper
patient
iii
borderlineresect
patient
associ
cytoreduct
surgeri
hipec
goldstandard
cur
treatment
condit
resect
system
chemotherapi
alon
yield
median
surviv
time
one
year
month
complet
cytoreduct
hipec
expert
center
rate
respons
standard
neoadjuv
chemotherapi
italian
french
experi
report
neg
effect
neoadjuv
chemotherapi
overal
surviv
resect
patient
borderlin
resect
form
usual
identifi
exploratori
laparoscopi
given
bidirect
neoadjuv
treatment
system
intraperiton
chemotherapi
result
secondari
resect
half
case
current
epidem
set
nonresect
borderlineresect
case
andor
poor
prognosi
factor
sarcomatoid
biphas
histolog
form
firstlin
system
chemotherapi
cisplatin
alimta
recommend
immedi
resect
case
cytoreduct
surgeryhipec
must
prioriti
propos
cytoreduct
surgeri
hipec
goldstandard
treatment
resect
pseudomyxoma
peritonei
firstlin
treatment
local
schedul
imposs
lowgrad
asymptomat
pmp
propos
deferr
highgrad
pmp
signetr
cell
propos
system
chemotherapi
folfox
capox
epidem
set
reduc
contact
sinc
french
prodig
random
trial
complet
cytoreduct
surgeri
associ
periop
system
chemotherapi
goldstandard
cur
treatment
colorect
periton
metastas
give
median
surviv
time
month
hipec
yet
demonstr
benefit
overal
diseasefre
surviv
associ
complet
cytoreduct
surgeri
howev
monocentr
studi
report
surviv
time
longer
month
case
surgeri
plu
hipec
system
chemotherapi
even
less
effect
periton
metastat
diseas
especi
mucin
liver
lung
metastas
still
control
diseas
extent
median
surviv
time
modern
system
chemotherapi
protocol
month
histolog
analysi
resect
periton
metastas
show
chemotherapi
achiev
signific
tumor
respons
patient
complet
respons
sampl
patient
difficult
predict
poor
respons
chemotherapi
factor
ra
braf
mutat
locat
right
primari
tumor
mucin
compon
account
could
help
grade
patient
risk
patient
whose
tumor
present
microsatellit
instabl
potenti
sensit
immunotherapi
could
condit
one
discuss
cur
treatment
strategi
difficult
current
epidem
set
three
main
reason
poor
prognosi
median
surviv
time
month
latest
studi
associ
cytoreduct
surgeri
hipec
ii
high
risk
postop
complic
therapeut
associ
iii
difficulti
pursu
current
recommend
neoadjuv
chemotherapi
flot
toxic
reason
case
periton
metastas
system
chemotherapi
alon
give
median
surviv
time
one
year
recent
french
multicentr
studi
report
signific
surviv
benefit
cytoreductionhipec
associ
surgeri
alon
irrespect
subgroup
studi
popul
strictli
select
patient
possibl
obtain
remiss
case
limit
diseas
median
surviv
attain
year
followup
therapeut
associ
subgroup
patient
favor
histolog
independ
signetr
cell
complet
cytoreduct
surgeri
associ
periop
system
chemotherapi
goldstandard
treatment
resect
colorect
periton
metastas
system
neoadjuv
chemotherapi
effect
welltoler
allow
cytoreduct
surgeri
delay
repeat
time
apprais
albeit
difficult
risk
evolut
toward
nonresect
time
give
prioriti
cytoreduct
surgeri
resect
colorect
metastas
unrespons
system
chemotherapi
discuss
addit
hipec
case
case
expert
center
must
increas
risk
postop
complic
therefor
mark
differ
prognosi
major
surgeri
strategi
hipec
requir
intens
postop
care
high
risk
sever
postop
complic
strategi
system
chemotherapi
soon
meet
problem
toler
efficaci
patient
involv
often
young
mean
age
hipec
group
cytochip
trial
year
immedi
resect
ovarian
metastasi
limit
extens
diagnos
digest
resect
expect
patient
unev
medic
histori
primari
surgic
cytoreduct
goldstandard
treatment
present
prognost
advantag
term
surviv
neoadjuv
chemotherapi
accord
recent
recommend
french
nation
cancer
institut
inca
epidem
set
must
therefor
take
prioriti
accord
local
possibl
pictur
patient
major
risk
postop
complic
advanc
age
obes
sever
cardiovascular
patholog
asa
iii
iv
would
justifi
neoadjuv
chemotherapi
case
diffus
cancer
requir
major
cytoreduct
surgeri
potenti
prolong
postop
intens
care
start
neoadjuv
chemotherapi
discuss
differ
surviv
rate
two
strategi
main
random
trial
evalu
strategi
must
discuss
particular
patent
mark
comorbid
hipec
cisplatin
complet
resect
recent
shown
potenti
surviv
benefit
random
studi
increas
postop
complic
report
howev
place
hipec
remain
larg
controversi
current
context
intens
develop
target
therapi
delay
interv
surgeri
six
chemotherapi
cours
must
discuss
case
case
multidisciplinari
meet
consid
local
condit
chemotherapi
respons
interv
hipec
must
also
discuss
case
case
expert
center
case
recurr
recent
studi
challeng
impact
surgeri
rel
system
chemotherapi
alon
antiangiogen
await
definit
result
desktop
studi
evalu
impact
complet
surgeri
platinumsensit
recurr
ago
select
criteria
although
result
come
significantli
favor
surgeri
diseasefre
surviv
impact
overal
surviv
yet
known
hipec
platinumsensit
recurr
still
evalu
random
trial
chipor
franc
et
hors
itali
recommend
outsid
trial
case
platinumresist
recurr
best
report
result
obtain
associ
surgeri
complet
cytoreduct
hipec
result
cytoreduct
surgeryhipec
associ
certain
rare
indic
patient
strictli
select
expert
center
collect
intern
psogi
group
work
reveal
notabl
long
surviv
time
unusu
indic
urachu
mucin
ovarian
tumor
cholangiocarcinoma
liver
cell
carcinoma
other
prognost
factor
found
popul
periton
metastasi
frequent
origin
complet
cytoreduct
surgeri
pci
level
scientif
proof
given
limit
retrospect
cohort
admittedli
high
possibl
must
consid
offer
access
treatment
patient
clearli
resect
diseas
favor
tumor
biolog
reflect
good
prolong
respons
chemotherapi
could
result
long
surviv
even
complet
remiss
priorit
primari
complet
cytoreduct
surgeri
immedi
resect
ovarian
metastas
limit
extens
accord
local
possibl
prefer
neoadjuv
chemotherapi
immedi
resect
periton
cancer
local
schedul
cytoreduct
surgeri
imposs
cancer
extens
discuss
delay
interv
surgeri
six
cours
multidisciplinari
meet
light
local
condit
respons
chemotherapi
consid
local
condit
priorit
indic
ensur
optim
periop
care
priorit
system
chemotherapi
whenev
control
diseas
accept
toler
epidem
abat
